TheraRadar
← Back
Data updated: Jun 28, 2026

PRAXAIR DISTRIBUTION INC

Pharma
Pharmaceuticals

PRAXAIR DISTRIBUTION INC is a pharmaceutical company with 3 FDA-approved products.

2013
Since
3
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
3 Small Molecules

PRAXAIR DISTRIBUTION INC's Key Drugs

PRAXAIR DISTRIBUTION INC's core commercial portfolio centers on NITROUS OXIDE, USP, MEDICAL AIR, USP, HELIUM, USP — its most strategically important drugs approved in the last 15 years.

NITROUS OXIDE, USP
Other
Approved 2013
MEDICAL AIR, USP
Respiratory
Approved 2013
HELIUM, USP
Respiratory
Approved 2013

PRAXAIR DISTRIBUTION INC's Recent FDA Approvals

PRAXAIR DISTRIBUTION INC secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

MEDICAL AIR, USP NDA
2026-02-17
MEDICAL AIR, USP NDA
2024-07-13
medical air

PRAXAIR DISTRIBUTION INC's Therapeutic Areas

Disease areas where PRAXAIR DISTRIBUTION INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

PRAXAIR DISTRIBUTION INC Pipeline Snapshot

Active clinical trials for PRAXAIR DISTRIBUTION INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • NITROUS OXIDE, USP leads revenue
  • • 3 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling